Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial

2020

The Lancet Oncology , Volume 21 - Issue 7 p. 935- 946

Additional Metadata
Persistent URL	hdl.handle.net/1765/130247
Journal	The Lancet Oncology
Rights	no subscription
Organisation	Department of Medical Oncology
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Heinrich, M., Jones, R., von Mehren, M., Schoffski, P, Serrano, C., Kang, YK, Cassier, P., Mir, O., Eskens, F., Tap, W.D., Rutkowski, P., Chawla, L., Trent, J., Tugnait, M., Evans, E.K., Lauz, T., Zhou, T., Roche, M., Wolf, B.B., … George, S. (2020). Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. The Lancet Oncology, 21(7), 935–946.http://hdl.handle.net/1765/130247

Publication